{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Patidegib",
    "query": {
      "intervention": "Patidegib"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Patidegib&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T16:27:35.906Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04155190",
      "title": "A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Basal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Patidegib Topical Gel, 2%",
          "type": "DRUG"
        },
        {
          "name": "Patidegib Topical Gel, Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sol-Gel Technologies, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-12-20",
      "completion_date": "2021-04-23",
      "has_results": true,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-09-08T16:27:35.906Z",
      "location_count": 14,
      "location_summary": "Apple Valley, California • Colton, California • Fremont, California + 11 more",
      "locations": [
        {
          "city": "Apple Valley",
          "state": "California"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04155190"
    },
    {
      "nct_id": "NCT04308395",
      "title": "Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Basal Cell Nevus Syndrome"
      ],
      "interventions": [
        {
          "name": "Patidegib Topical Gel, 2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sol-Gel Technologies, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2020-06-03",
      "completion_date": "2021-07-14",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-09-08T16:27:35.906Z",
      "location_count": 17,
      "location_summary": "Fremont, California • Newport Beach, California • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04308395"
    },
    {
      "nct_id": "NCT01255800",
      "title": "Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "IPI-926 and Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2011-04",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-01-31",
      "last_synced_at": "2026-09-08T16:27:35.906Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01255800"
    },
    {
      "nct_id": "NCT01130142",
      "title": "A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "IPI-926 plus gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2010-04",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2017-03-06",
      "last_synced_at": "2026-09-08T16:27:35.906Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • San Diego, California • San Francisco, California + 21 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01130142"
    },
    {
      "nct_id": "NCT02828111",
      "title": "Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Basal Cell Carcinomas"
      ],
      "interventions": [
        {
          "name": "Patidegib",
          "type": "DRUG"
        },
        {
          "name": "Vehicle gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PellePharm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 36,
      "start_date": "2016-11-11",
      "completion_date": "2017-11-09",
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-09-08T16:27:35.906Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02828111"
    },
    {
      "nct_id": "NCT01310816",
      "title": "A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Conventional Chondrosarcoma"
      ],
      "interventions": [
        {
          "name": "IPI-926",
          "type": "DRUG"
        },
        {
          "name": "Placebo Arm",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2011-02",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2013-12-05",
      "last_synced_at": "2026-09-08T16:27:35.906Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01310816"
    },
    {
      "nct_id": "NCT01609179",
      "title": "IPI-926 Extension Protocol for Continuation of Treatment With IPI-926",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Basal Cell Carcinoma",
        "Chondrosarcoma"
      ],
      "interventions": [
        {
          "name": "IPI-926",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2012-03",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2012-11-14",
      "last_synced_at": "2026-09-08T16:27:35.906Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Baltimore, Maryland",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01609179"
    },
    {
      "nct_id": "NCT00761696",
      "title": "A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "IPI-926",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2008-09",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2012-06-21",
      "last_synced_at": "2026-09-08T16:27:35.906Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Redwood City, California • Aurora, Colorado + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00761696"
    },
    {
      "nct_id": "NCT01383538",
      "title": "FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Adenocarcinoma",
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "FOLFIRINOX, IPI-926",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew Ko",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2011-08-23",
      "completion_date": "2015-05-26",
      "has_results": false,
      "last_update_posted_date": "2017-08-08",
      "last_synced_at": "2026-09-08T16:27:35.906Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Chicago, Illinois • Madison, Wisconsin",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01383538"
    },
    {
      "nct_id": "NCT03703310",
      "title": "Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Basal Cell Nevus Syndrome"
      ],
      "interventions": [
        {
          "name": "Patidegib Topical Gel, 2%",
          "type": "DRUG"
        },
        {
          "name": "Patidegib Topical Gel, Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sol-Gel Technologies, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2019-02-19",
      "completion_date": "2020-12-28",
      "has_results": true,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-09-08T16:27:35.906Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Newport Beach, California • Redwood City, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03703310"
    }
  ]
}